Pharmacotherapy of Obesity

Obesity Management

Volumn 1, Issue 1, 2005, Pages 15-19

  Waitman, Jonathan A ^a   Aronne, Louis J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 53549122036     PISSN: 15451712     EISSN: None     Source Type: Journal    
DOI: 10.1089/obe.2005.1.15     Document Type: Article

References (22)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002;288(14):1723–1727.
2. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004;29(10):1238–1245.
3. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393–403.
4. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB. Sibutramine produces dose-related weight loss. Obes Res 1999;7(2):189–198.
5. Wirth A, Krause J. Long-term weight loss with sibutramine: A randomized controlled trial. JAMA 2001;286(11):1331–1339.
6. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002;16(1):5–11.
7. Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: A placebo-controlled, double-blind, randomized trial. J Hum Hypertens 2002;16(1):13–19.
8. Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, Hanotin C, Igau B, Drouin P. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002;144(3):508–515.
9. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56(1):82–85.
10. Carriere F, Renou C, Ransac S, Lopez V, De Caro J, Ferrato F, De Caro A, Fleury A, Sanwald-Ducray P, Lengsfeld H, Beglinger C, Hadvary P, Verger R, Laugier R. Inhibition of gastrointestinal lipolysis by orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2001;281(1):616–628.
11. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155–161.
12. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized, double-blind study. Diabetes Care 1998;21(8):1288–1294.
13. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Rel Metab Disord 2001;25(7):1095–1099.
14. Stafford RS, Radley DC. National trends in antiobesity medication use. Arch Intern Med 2003;163(9):1046–1050.
15. Munro JF, MacCuish AC, Wilson EM, Duncan LJP. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968;10:352–354.
16. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N. Evaluation of the safety and efficacy of subutramine, orlistat, and metformin in the treatment of obesity. Diabetes Obes Metab 2002;4(1):49–55.
17. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50(12):1457–1461.
18. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003;11(4):556–562.
19. McElroy SL, Suppes T, Keck PE, Jr, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47:1025–1033.
20. Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. Topiramate use in obese patients with binge eating disorder: An open study. Can J Psychiatry 2002;47(3):271–273.
21. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11(6): 722–733.
22. Gadde KM, Franciscy DM, Wagner II HR, Ranga K, Krishnan R. Zonisamide for weight loss in obese adults: A randomized controlled trial. JAMA 2003;289:1820–1825